*ST双成：依替巴肽注射液获澳大利亚上市许可

Core Viewpoint - The company ST Shuangcheng (002693) has received marketing approval for Eptifibatide injection from the Australian Therapeutic Goods Administration, which is expected to enhance its overseas market expansion and improve performance [1] Group 1: Product Approval - Eptifibatide injection is indicated for patients undergoing non-emergency percutaneous coronary intervention and coronary artery stenting, as well as for treating unstable angina or non-Q-wave myocardial infarction [1] - The product has already received marketing approval from the US FDA and is widely sold globally [1] Group 2: Market Impact - The approval in Australia will assist the company in expanding its overseas market presence [1] - The company cautions that export sales of the drug may be influenced by market demand, policy environment, exchange rates, and market competition, indicating potential uncertainties [1]